TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02393417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CANDIN
Description: Candida albicans Skin Test Antigen for Cellular Hypersensitivity

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CANDIN
Description: Candida albicans Skin Test Antigen for Cellular Hypersensitivity

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CANDIN
Description: Candida albicans Skin Test Antigen for Cellular Hypersensitivity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection USP (non-preserved)
Study: NCT03875911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Three delivery methods of Mitomycin-C in Trabeculectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Three delivery methods of Mitomycin-C in Trabeculectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Three delivery methods of Mitomycin-C in Trabeculectomy
Study: NCT02144519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Physical Activity
Description: Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Physical Activity
Description: Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
Study: NCT01435044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
Study: NCT03254173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine 30 mg oral tablets
Description: Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablets
Description: Placebo oral tablets , half tablet daily before sleep for 8 weeks
Study: NCT04310644

Intervention type: OTHER
Intervention: No intervention planned, but all patients get our standart treatment
Description: Patients are selected from clinical Routine and get our standart Treatment based on their disease

Intervention type: OTHER
Intervention: No intervention planned, but all patients get our standart treatment
Description: Patients are selected from clinical Routine and get our standart Treatment based on their disease

Intervention type: OTHER
Intervention: No intervention planned, but all patients get our standart treatment
Description: Patients are selected from clinical Routine and get our standart Treatment based on their disease
Study: NCT02620020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Participants received fasinumab SC or IV, Q4W or Q8W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Participants received fasinumab SC or IV, Q4W or Q8W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Participants received fasinumab SC or IV, Q4W or Q8W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
Study: NCT00691665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine HCL Nasal Spray, 0.6%
Description: Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Nasal Spray, 50 mcg
Description: Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
Study: NCT04116099

Intervention type: OTHER
Intervention: Conservative care
Description: May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.

Intervention type: OTHER
Intervention: Conservative care
Description: May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.

Intervention type: DEVICE
Intervention: Flexitouch Plus
Description: Flexitouch Plus treatment.
Study: NCT06042374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Core Stabilization Training
Description: The Progressive Core Stabilization Training was applied to study group as a group exercise with 5-10 athletes which was planned in the form of 3 days/week for a total of 9 weeks and 27 sessions. A session consisted of warm-up, core stabilization (30-40 min.), and cool-down exercises. During the training period, exercise volume, degree of difficulty, additional weight, and level of instability (contralateral limb movements and reduction of the support surface, etc.) for each exercise were incrementally increased in four steps.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Core Strengthening Exercises
Description: The athletes included in the CG performed only Standard Core Strengthening Exercises which is the first phase of the Progressive Core Stabilization Training on fixed surfaces (i.e. without pads and balls, with a flat floor and a bench) for 3 days/week and totally 9-week.
Study: NCT02868892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2
Study: NCT01012908

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Norzyme - Bergamo
Description: 2 - 8 tablets per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creon
Description: 2 - 8 tablets pet day
Study: NCT02131844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated early mobilization
Description: Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
Study: NCT04378777

Intervention type: PROCEDURE
Intervention: Biological sample collection
Description: During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study \[GWAS\]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
Study: NCT01435044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0938
Description: GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0938
Description: GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0938
Description: GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match sofosbuvir
Description: Placebo to match sofosbuvir administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match sofosbuvir
Description: Placebo to match sofosbuvir administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GS-0938
Description: Placebo to match GS-0938 administered orally once daily
Study: NCT02836613

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Galcanezumab
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study: NCT02276378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan low

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan high
Study: NCT04378777

Intervention type: PROCEDURE
Intervention: Data Collection: Clinical Care Assessments
Description: Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
Study: NCT02984462

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous Akin osteotomy
Description: The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
Study: NCT02252367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil 5 mg once daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily for 12 weeks.
Study: NCT04048512

Intervention type: PROCEDURE
Intervention: Resection with intraoperative use of ECMO/CPB
Description: Patients are operated with the use of intraoperative ECMO/CPB

Intervention type: PROCEDURE
Intervention: Resection without intraoperative use of ECMO/CPB
Description: Patients are operated without the use of intraoperative ECMO/CPB
Study: NCT02928952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-STRIDE
Description: Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
Study: NCT00719199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2055
Description: SC weekly injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Given day 1 of each cycle
Study: NCT04586491

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral care protocol
Description: Oral care protocol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral care protocol
Description: Oral care protocol
Study: NCT03216993

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol care
Description: Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
Study: NCT02100384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-implant maintenance
Description: The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-implant maintenance
Description: The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
Study: NCT01755169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
Study: NCT01223820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 5x nasal application in one day, 1 hour between each application
Study: NCT00675935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Prevention Tool Kit prototype using a randomized design
Description: Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
Study: NCT02907047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tourniquet inflated

Intervention type: OTHER
Group type: OTHER
Intervention: tourniquet not inflated
Study: NCT01755169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00900003

Intervention type: GENETIC
Intervention: protein analysis
Description: Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
Study: NCT04539470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efmarodocokin Alfa
Description: Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.
Study: NCT01360996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/20 μg EE
Description: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/20 μg EE
Description: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/20 μg EE
Description: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
Study: NCT02537678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care TF-CBT
Description: Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
Study: NCT04539470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efmarodocokin Alfa
Description: Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efmarodocokin Alfa
Description: Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.
Study: NCT02537678

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard TF-CBT
Description: Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
Study: NCT03806244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative acquisition (robotic c-Arm) of images
Description: Conventional laparoscopic colorectal oncologic resection is performed. During the procedure, the operator will identify previously defined anatomical landmarks, point them with an instrument tracked by the navigation system and the accuracy of the stereotactic navigation system will be calculated by comparing the surgical anatomical point and its correspondent on the images of the navigation platform.
Study: NCT02735213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 577-MPL
Description: 9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250\~400 milliWatts of power(50% threshold power),150\~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TLT
Description: contimuous wave,100um spot size, 0.05 seconds duration, 55\~60 milliwatts of power, 18\~27 spots,the laser area is the corresponding leakage on mid-phase FA.
Study: NCT00222105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Doxil 40 mg/m2 IV day 1
Study: NCT03985865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intragastric quinine hydrochloride
Description: A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intragastric denatonium benzoate
Description: A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intragastric placebo
Description: A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
Study: NCT02276378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese meal
Study: NCT03627611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin
Description: 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: 3 months
Study: NCT04543370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edasalonexent 2000 mg TID
Description: CAT-1004 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 2 MG/ML
Description: 2 mg/ml syrup